Search

Displaying results 8001 - 8010 of 10000 in total
  1. Drug

    RG2417

    go.drugbank.com/drugs/DB05055
    Investigational

    RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential … Uridine is synthesized by the mitochondria, the power plant of the human cell responsible for energy metabolism.

  2. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 is a new class of medicaction for treatment of cardiometabolic disease. … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.

  3. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). … The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.

  4. Drug

    ACE393

    go.drugbank.com/drugs/DB05071
    Investigational

    ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.

  5. Drug

    TG-100801

    go.drugbank.com/drugs/DB05075
    Investigational

    TG100801 is a topically applied kinase inhibitor in macular degeneration patients. … It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 is an analogue of the natural hormone Pancreatic Polypeptide (PP), which is released in connection with meals. … TM30339 thus imitates a natural mechanism, a satiety signal from the gastrointestinal system involved in the regulation of food intake in humans. TM30339 is developed for the treatment of obesity.

  7. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    Ganaxolone is the 3β-methylated synthetic analog of [allopregnanolone],[L41130] a metabolite of [progesterone].[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [A245995] Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABA<sub>A</sub> receptors.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  8. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. … And this is where the double neurotherapeutic approach is most beneficial: AX200 stops neuronal cell death in the acute phase of stroke, while stimulating simultaneously the regeneration of nervous tissue

  9. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. … Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

  10. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect.

    Categories: Venombin A